Skip to main content

Table 3 Comparison of complications, treatment, and clinical outcomes of three types hospitalized influenza-related viral pneumonia patients

From: A comparison of demographic, epidemiological and clinical characteristics of hospital influenza-related viral pneumonia patients

Characteristics

B (n = 59)

A (n = 138)

H7N9 (n = 18)

p-value among

(a)

(b)

(c)

(a) and (b)

(a), (b), and (c)

Complications

7 (12)

16 (12)

4 (22.2)

0.957

0.411

 Shock

1 (1.7)

9 (6.5)

1 (5.6)

0.289

0.315

 Acute kidney injury

5 (8.5)

11 (8)

2 (11.1)

1

0.793

 Rhabdomyolysis

1 (1.7)

1 (0.7)

1 (5.6)

0.51

0.147

Treatment

 Oxygen therapy, no. (%)

44 (74.6)

101 (73.2)

18 (100)

0.84

0.022

 Antiviral treatment, no. (%)

52 (88)

152 (93)

18 (100)

0.72

0.388

  Oseltamivir

36 (69.2)

70 (56.5)

0 (0)

0.114

< 0.001

  Peramivir

9 (17.3)

32 (25.8)

0 (0)

0.224

0.02

  Both

7 (13.5)

22 (17.7)

18 (100)

0.485

< 0.001

Timing from onset of illness to administration of antiviral therapy, median (IQR) (days)

6 (3–14)

7 (5–10.8)

4 (3–8.3)

0.797

0.089

 0–2

9 (17.6)

14 (11.3)

1 (18)

0.258

0.384

 3–5

12 (23.5)

31 (25)

57 (34.8)

0.837

0.091

 ≥ 6

30 (58.8)

79 (63.7)

8 (44.4)

0.544

0.281

Timing from administration of antiviral therapy to virus negative, median (IQR)

11 (6–17.75)

10 (6–14.5)

5 (2.8–10)

0.26

0.007

Admission to ICU, no. (%)

4 (6.8)

27 (19.6)

15 (83.3)

0.024

0.054

Mechanical ventilation

 Noninvasive

6 (10.2)

14 (10.1)

0 (0)

0.996

0.528

 Invasive

2 (3.4)

23 (16.7)

7 (38.9)

0.001

0.001

Extracorporeal membrane oxygenation

0 (0)

2 (1.4)

2 (11.1)

1

0.048

Blood purification

4 (6.8)

3 (2.2)

2 (11.1)

0.2

0.072

Antibiotics

56 (94.9)

134 (97.1)

17 (94.4)

0.430

0.416

Antifungal

22 (37.3)

42 (30.4)

13 (72.2)

0.347

0.002

Glucocorticoids

24 (41)

77 (56)

18 (100)

0.052

< 0.001

Clinical outcome

 Death

5 (8.5)

13 (9.4)

0 (0)

0.833

0.542

 Total hospitalization expenses (Yuan), median (IQR)

18,316.8 (11,111.1–35,750.5)

25,642.3 (13,184.5–53,805.7)

66,095.6 (42,450.6–129,574.2)

0.094

< 0.001

  1. Timing from onset of illness to administration of antiviral therapy: For human influenza A, there were 14 miss dates; for B, there were 8 miss dates
  2. Timing from administration of antiviral therapy to virus negative: For human influenza A, there were 73 miss dates; for B, there were 39 miss dates
  3. Total hospitalization expenses: For human influenza A, there were 14 miss dates; for B, there were 6 miss dates
  4. ICU intensive care unit, IQR interquartile range